Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CARM 
Carisma Therapeutics Inc. (CARM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CARM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.62% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.53M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 2 | Beta 3.71 | 52 Weeks Range 0.14 - 1.27 | Updated Date 08/29/2025 |
52 Weeks Range 0.14 - 1.27 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.53 | Actual -0.23 |
Profitability
Profit Margin - | Operating Margin (TTM) -409.69% |
Management Effectiveness
Return on Assets (TTM) -85.68% | Return on Equity (TTM) -362.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9228685 | Price to Sales(TTM) 0.88 |
Enterprise Value 9228685 | Price to Sales(TTM) 0.88 | ||
Enterprise Value to Revenue 0.86 | Enterprise Value to EBITDA -0.06 | Shares Outstanding 41788100 | Shares Floating 31931956 |
Shares Outstanding 41788100 | Shares Floating 31931956 | ||
Percent Insiders 27.76 | Percent Institutions 26.32 |
Upturn AI SWOT
Carisma Therapeutics Inc.
Company Overview
History and Background
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies for the treatment of cancer. Founded in 2016, Carisma is pioneering the development of CAR-Macrophage therapies.
Core Business Areas
- CAR-Macrophage Immunotherapy: Development of chimeric antigen receptor (CAR)-engineered macrophages for cancer treatment.
Leadership and Structure
The leadership team includes Steven Kelly (President and CEO). The organizational structure is typical of a clinical-stage biotech, focused on R&D, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- CT-0508 (CAR-Macrophage for HER2+ Solid Tumors): CT-0508 is Carisma's lead CAR-Macrophage product candidate, currently in Phase 1 clinical trials for HER2-positive solid tumors. Market share data is not yet available as the product is in development. Key competitors include companies developing CAR-T cell therapies for solid tumors, such as Roche (ROG.SW) and Bristol Myers Squibb (BMY).
Market Dynamics
Industry Overview
The immunotherapy market is experiencing significant growth, driven by advancements in CAR-T cell therapy and other immune-based approaches. Solid tumors remain a significant unmet need, driving innovation in areas like CAR-Macrophage therapy.
Positioning
Carisma Therapeutics is positioned as a pioneer in CAR-Macrophage technology, potentially offering advantages over CAR-T cells in solid tumor penetration and immune modulation.
Total Addressable Market (TAM)
The TAM for solid tumor immunotherapies is estimated to be in the tens of billions of dollars annually. Carisma is positioned to capture a share of this market if CT-0508 proves effective.
Upturn SWOT Analysis
Strengths
- Pioneering CAR-Macrophage technology
- Potential for improved solid tumor penetration compared to CAR-T cells
- Strong scientific leadership
- First-in-class approach
Weaknesses
- Early stage clinical development
- Limited clinical data available
- High research and development costs
- Dependent on financing
Opportunities
- Successful clinical trial outcomes for CT-0508
- Partnerships with larger pharmaceutical companies
- Expansion to additional cancer targets
- Advancements in macrophage engineering
Threats
- Clinical trial failures
- Competition from established CAR-T cell therapies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- BMY
- GILD
- JNJ
Competitive Landscape
Carisma Therapeutics faces competition from established pharmaceutical companies with CAR-T cell therapies and other immunotherapy platforms. Carisma's advantage lies in its pioneering CAR-Macrophage technology.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily reflected in the expansion of the research and development pipeline and the advancement of CT-0508 through clinical trials.
Future Projections: Future growth is dependent on clinical trial success, regulatory approvals, and commercialization of CAR-Macrophage therapies. Analyst estimates vary significantly.
Recent Initiatives: Recent initiatives include the advancement of CT-0508 into Phase 1 clinical trials and the expansion of the CAR-Macrophage pipeline.
Summary
Carisma Therapeutics is an early-stage biotech company pioneering CAR-Macrophage therapy, presenting a potentially revolutionary solid tumor treatment. While innovative, Carisma faces significant risks including clinical trial uncertainty and competition. Strong financing is crucial for continued development, with potential for growth contingent on CT-0508 success. It needs to outperform against competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Corporate Presentation
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Carisma Therapeutics Inc.
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2014-02-06 | President, CEO & Director Mr. Steven Kelly | ||
Sector Healthcare | Industry Biotechnology | Full time employees 46 | Website https://www.carismatx.com |
Full time employees 46 | Website https://www.carismatx.com | ||
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.